医学临床研究
   Jul. 15, 2025    Home  |  About Journal  |  Editorial Board  |  Instruction  |  Subscribe  |  Advertisement  |  Messages Board  |  Contact Us  |  中文
JOURNAL OF CLINICAL RESEARCH  2024, Vol. 41 Issue (9): 1354-1357    DOI: 10.3969/j.issn.1671-7171.2024.09.020
Original Articles Current Issue | Archive | Adv Search |
Efficacy of Budesonide-Formoterol Inhalation Aerosol in Treating High-Risk Acute Exacerbations of Chronic Obstructive Pulmonary Disease Patients
ZHU Yanjing, CHEN Peijie, JI Xiaoli, et al
Department of Respiratory and Critical Care Medicine, Jing'an District Central Hospital, Shanghai 200040
Download: PDF (1210 KB)   HTML (1 KB) 
Export: BibTeX | EndNote (RIS)       Supporting Info
Abstract  【Objective】To investigate the efficacy and safety of Budesonide-Formoterol inhalation aerosol in treating high-risk acute exacerbations of chronic obstructive pulmonary disease (COPD).【Methods】A total of 160 patients with high-risk acute exacerbations of COPD were randomly divided into the observation group (treated with Budesonide-Formoterol inhalation aerosol) and the control group (treated with Indacaterol-Glycopyrronium inhalation powder capsules), with 80 cases in each group. The differences in pulmonary function indicators, blood gas indicators, COPD assessment test (CAT) scores, modified Medical Research Council (mMRC) dyspnea scale scores, exercise endurance [six-minute walk distance (6MWD)] and quality of life (SGRQ) scores before treatment, and at 3 months and 6 months after treatment were compared between the two groups.【Results】 After 3 and 6 months of treatment, the pulmonary function indicators and blood gas indicators of the observation group were significantly better than those of the control group (P<0.05). The mMRC, CAT, and respiratory symptom scores in the SGRQ scale of the observation group were lower than those of the control group (P<0.05), and the 6MWD was higher than that of the control group (P<0.05). However, there was no statistically significant difference in daily activities, disease symptoms, and total scores on the SGRQ scale between the two groups (P>0.05). There was no statistically significant difference in the total incidence of adverse reactions between the two groups (P>0.05).【Conclusion】 Budesonide-Formoterol inhalation aerosol is effective in treating high-risk acute exacerbations of COPD and it does not increase the incidence of adverse drug reactions.
Key wordsPulmonary Disease, Chronic Obstructive/DT      Bronchodilator Agents/PD      Treatment Outcome     
Received: 20 December 2023     
PACS:  R563  
Service
E-mail this article
Add to my bookshelf
Add to citation manager
E-mail Alert
RSS
Articles by authors
ZHU Yanjing
CHEN Peijie
JI Xiaoli
et al
Cite this article:   
ZHU Yanjing,CHEN Peijie,JI Xiaoli, et al. Efficacy of Budesonide-Formoterol Inhalation Aerosol in Treating High-Risk Acute Exacerbations of Chronic Obstructive Pulmonary Disease Patients[J]. JOURNAL OF CLINICAL RESEARCH, 2024, 41(9): 1354-1357.
URL:  
http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2024.09.020     OR     http://journal07.magtech.org.cn/yxlcyj/EN/Y2024/V41/I9/1354
Copyright © Editorial Board of JOURNAL OF CLINICAL RESEARCH
Supported by:Beijing Magtech